Senseonics (NYSE:SENS) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Stock Performance

Shares of NYSE SENS opened at $0.35 on Tuesday. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17. The business has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $0.42. The firm has a market cap of $185.01 million, a PE ratio of -2.49 and a beta of 0.79. Senseonics has a twelve month low of $0.32 and a twelve month high of $0.75.

Senseonics (NYSE:SENS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The business had revenue of $4.87 million for the quarter, compared to the consensus estimate of $4.86 million. Analysts expect that Senseonics will post -0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC increased its holdings in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares during the period. Virtu Financial LLC acquired a new position in Senseonics during the 1st quarter valued at about $162,000. Price T Rowe Associates Inc. MD increased its position in Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares in the last quarter. Vanguard Group Inc. increased its position in Senseonics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in Senseonics during the 1st quarter valued at about $91,000. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.